



Change in Financial Year End

Brisbane, Australia 23rd January 2018: Factor Therapeutics Limited (ASX: FTT, the “Company”), an Australian biomedical company developing therapeutics for advanced wound care, advises that the Board has resolved to change the Company’s financial year end date from 30 June to 31 December.

The change has been made to facilitate the Company’s preparations for the readout from the VF00102 clinical trial.

The Company has made the change in financial year end in accordance with section 323D (2A) of the Corporations Act 2001 (Cth). The Board confirms that:

- The Company’s previous financial year ended on 30 June 2017;
- The Company will have a six-month transitional financial year beginning on 1 July 2017 and ending on 31 December 2017; and
- Thereafter, the Company will revert to a twelve-month financial year, commencing on 1 January and ending on 31 December.

The change in financial year requires the Company to, in respect of the transitional financial year:

- Lodge an Appendix 4E by 28 February 2018;
- Lodge audited Financial Statements by 31 March 2018; and
- Hold an annual general meeting by 31 May 2018, the date of which will be determined and advised in due course.

-ENDS-

For Further Information Contact

Dr. Rosalind Wilson
Chief Executive Officer
Factor Therapeutics Limited
r.wilson@factor-therapeutics.com

About Factor Therapeutics

Factor Therapeutics Limited (“Factor”) is a biomedical technology company that is developing treatments for acute and chronic wound healing applications. Factor is a clinical stage company with its lead program (VF-001) in Phase II for the treatment of venous leg ulcers (VLUs). The company is also developing solutions for a variety of interventional wound care and serious orphan dermatology conditions. The company’s platform technology originates from the Institute of Health and Biomedical Innovation at the Queensland University of Technology (QUT), Australia. Factor’s shares are traded on the Australian Securities Exchange (ASX) under the ticker FTT. For more information, please visit <https://factor-therapeutics.com>.